Crossmark

Rivaroxaban versus low molecular weight heparin for managing lower extremity deep vein thrombosis following thoracoscopic lung cancer surgery: a randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s13019-024-03225-5

Published Online: 2025-01-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Lidan

Wu, Di

Li, Liang

Zhao, Qin

Yang, Hailing

Han, Xiaoyong

Liu, Liang

Gao, Lu
Funding

Funding for this research was provided by:

Baoding City Key Laboratory of Diagnosis and Treatment of Pulmonary Nodules
License Information

Text and Data Mining valid from 2025-01-20

Version of Record valid from 2025-01-20
More Information

Article History

Received: 10 July 2024

Accepted: 24 December 2024

First Online: 20 January 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below